Cambium BIO Limited (ASX: CMB)
Sector: Health Care
Market cap: A$12M (as of 2 Nov 2026)
Cambium Bio is a patient-focused, clinical-stage, regenerative medicine company developing a pioneering platform in ophthalmology and tissue regeneration
Data as of 2 Nov 2026.
Recent capital raises
Substantial holders — latest moves
| Date | Holder | Move | Holding | Source |
|---|---|---|---|---|
| 24 July 2026 | Wu Chun-Yi (also known as Brandon Wu) | Increase | 12.25% → 18.51% | Filing ↗ |
| 24 June 2026 | Wu Chun-Yi | Entry | — | Filing ↗ |
| 24 June 2026 | Zheng Yang Biomedical Technology Co., Ltd. % Yu-Hung Sebastian Tseng | Increase | 22.530% → 39.610% | Filing ↗ |
| 16 June 2026 | Mr Chen Tsung Chi | Entry | — | Filing ↗ |
| 29 Aug 2025 | ZHENG YANG BIOMEDICAL TECHNOLOGY LIMITED | Entry | ?% → 35.35% | Filing ↗ |
Director trades — on-market
| Date | Director | Trade | Source |
|---|---|---|---|
| 1 Sept 2020 | Leo Yao Lee | Bought 2,379,893 fully paid ordinary shares | Filing ↗ |
Cash and runway
Ask about CMB in Claude or ChatGPT
Add the Capital Signal connector at https://capitalsignal.io/api/mcp, then ask:
- Has CMB raised money in the last year, and at what discount?
- What was CMB's latest cash position and runway?
Loading CMB…